Axium to distribute Elaprase

LAKE MARY, Fla. Specialty pharmacy provider Axium Healthcare Pharmacy will serve as a limited distribution provider for a drug to treat a serious genetic disorder, Axium said Monday.

Axium will distribute Shire Human Genetic Therapies’ Elaprase (idursulfase), used to treat Hunter syndrome, also known as mucopolysaccharidosis II. According to the Mayo Clinic, Hunter syndrome causes chains of sugar molecules to build up in the body over time, resulting in mental deficiency and retardation, deformities, deafness and other symptoms. The juvenile-onset form of the disease typically results in death in the early teens to early 20s, while those with the late-onset form live for 20 to 60 years. It mostly affects boys.

“Axium is pleased to be granted the opportunity to be a provider of Elaprase in Puerto Rico,” Axium president and CEO Mark Montgomery said. “This selection continues to build momentum on Axium’s strong clinical programs and our investment in providing solutions for our clients.”